Ming Yan - Feb 10, 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Chief Technology Officer, Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Ming Yan
Stock symbol
CTKB
Transactions as of
Feb 10, 2022
Transactions value $
-$302,106
Form type
4
Date filed
2/14/2022, 05:23 PM
Previous filing
Feb 14, 2022
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Sale -$221K -14.7K -0.18% $15.01 8.12M Feb 10, 2022 Direct F1, F2
transaction CTKB Common Stock Sale -$81.4K -5.29K -0.07% $15.37 8.11M Feb 10, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.26 to $15.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.27 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.